10.16
-0.16(-1.55%)
Currency In USD
| Previous Close | 10.32 |
| Open | 10.3 |
| Day High | 10.39 |
| Day Low | 9.88 |
| 52-Week High | 47.45 |
| 52-Week Low | 6.36 |
| Volume | 1.77M |
| Average Volume | 2.72M |
| Market Cap | 1.15B |
| PE | -2.81 |
| EPS | -3.61 |
| Moving Average 50 Days | 11.47 |
| Moving Average 200 Days | 20.16 |
| Change | -0.16 |
If you invested $1000 in Dyne Therapeutics, Inc. (DYN) since IPO date, it would be worth $425.1 as of June 24, 2025 at a share price of $10.16. Whereas If you bought $1000 worth of Dyne Therapeutics, Inc. (DYN) shares 3 years ago, it would be worth $1,487.55 as of June 24, 2025 at a share price of $10.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
GlobeNewswire Inc.
Jun 17, 2025 11:00 AM GMT
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
GlobeNewswire Inc.
Jun 16, 2025 8:05 PM GMT
WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven disease
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
GlobeNewswire Inc.
Jun 05, 2025 11:30 AM GMT
- DYNE-302 Demonstrated Functional Improvement in an FSHD Preclinical Model - WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for